title: Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.
abstract: Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients.
  
  
  METHODS
  Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival.
  
  
  RESULTS
  Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004-0.63; n = 34; P = 0.019) were associated with longer survival.
  
  
  CONCLUSIONS
  (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Marincek
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Radojewski
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland Department of Radiology, David Geffen School of Medicine, UCLA, Los Angeles, California.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Dumont
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Philippe
authors.initials: P
authors.lastname: Brunner
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Jan
authors.initials: J
authors.lastname: Müller-Brand
authors.affiliation: Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland.
authors.forename: Helmut R
authors.initials: HR
authors.lastname: Maecke
authors.affiliation: Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; and.
authors.forename: Matthias
authors.initials: M
authors.lastname: Briel
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California m.a.walter@gmx.net.
authors.forename: Martin A
authors.initials: MA
authors.lastname: Walter
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016543:Central Nervous System Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008579:Meningioma / Q000401:mortality / Q000532:radiotherapy*; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives* / Q000737:chemistry; D016016:Proportional Hazards Models; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000737:chemistry*; D016896:Treatment Outcome
chemical_list: C504257:177Lu-octreotide, DOTA(0)-Tyr(3)-; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide
keywords: metabolic therapy; sstr2; survival; targeted therapy